Odepharma SA
1.9 FTEThe score of Odepharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +618 % Total assets +28 % Headcount (avg FTE) +6 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Odepharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 69,636 € | ||||
| Equity | 115,621 € | ||||
| Cash | 57,952 € | ||||
| EBITDA | 88,126 € | ||||
| Total assets | 255,295 € |
Filed annual accounts
- Year ended 30 Sep 2025filed on 03 Feb 2026
- Year ended 30 Sep 2024filed on 27 Mar 2025
- Year ended 30 Sep 2023filed on 22 Apr 2024
- Year ended 30 Sep 2022filed on 28 Apr 2023
- Year ended 30 Sep 2021filed on 28 Apr 2022
Odepharma's financial analysis
- Solvency45.3%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Odepharma
Odepharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0441.639.812
- VAT number
- BE0441639812
- Peppol
- Registered · 0208:0441639812 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 12 Sep 1990
- Registered office
- 8670 Koksijde
- Size
- Micro · 1.9 FTE
- Latest accounts
- 2025 · filed on 03 Feb 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Odepharma (SA) has been based in Koksijde since 1990, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 69,636 € and equity of 115,621 €; its revenue is not published. With 1.9 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 45.3%, above the median of its sector (44.2%).
Companies similar to Odepharma
Companies in the same business, of comparable size and area, outside its group.
- Pharma VAL Retail sale of pharmaceutical products Profondeville · balance sheet 255,460 €
- Medphar Retail sale of pharmaceutical products Schaerbeek · balance sheet 255,858 €
- Hesbiphar Retail sale of pharmaceutical products Hannut · balance sheet 255,869 €
- Pharmacie Merelle Retail sale of pharmaceutical products Quévy · balance sheet 256,663 €
- MaPharma Retail sale of pharmaceutical products Charleroi · balance sheet 256,730 €
- Apotheek Brackenier en Demuynck Retail sale of pharmaceutical products Knokke-Heist · balance sheet 253,034 €
- Pharmadeville Retail sale of pharmaceutical products Bernissart · balance sheet 257,934 €
- Yasmin Libbrecht Retail sale of pharmaceutical products Antwerp · balance sheet 258,250 €
Frequently asked questions about Odepharma
What is the revenue of Odepharma?
Odepharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Odepharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0441639812 for Odepharma, if the company is VAT-registered. Its company number (CBE) is 0441.639.812.
Where is the registered office of Odepharma?
According to the CBE register, the registered office of Odepharma is in 8670 Koksijde.
What is the equity of Odepharma?
At the close of the 2025 financial year, the equity of Odepharma amounts to 115,621 €, a solvency of 45.3% of total assets.
How many people work at Odepharma?
1.9 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Odepharma?
The register lists 2 active mandates at Odepharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Odepharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →